DK2054073T3 - Farmaceutiske præparater til fremføring med langvarig frigivelse af peptider - Google Patents
Farmaceutiske præparater til fremføring med langvarig frigivelse af peptiderInfo
- Publication number
- DK2054073T3 DK2054073T3 DK07810318T DK07810318T DK2054073T3 DK 2054073 T3 DK2054073 T3 DK 2054073T3 DK 07810318 T DK07810318 T DK 07810318T DK 07810318 T DK07810318 T DK 07810318T DK 2054073 T3 DK2054073 T3 DK 2054073T3
- Authority
- DK
- Denmark
- Prior art keywords
- peptides
- pharmaceutical compositions
- sustained release
- sustained
- release
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- 238000013268 sustained release Methods 0.000 title 1
- 239000012730 sustained-release form Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1808—Epidermal growth factor [EGF] urogastrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Vascular Medicine (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US83001106P | 2006-07-11 | 2006-07-11 | |
PCT/US2007/015770 WO2008008363A1 (en) | 2006-07-11 | 2007-07-11 | Pharmaceutical compositions for sustained release delivery of peptides |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2054073T3 true DK2054073T3 (da) | 2015-03-02 |
Family
ID=38923538
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK07810318T DK2054073T3 (da) | 2006-07-11 | 2007-07-11 | Farmaceutiske præparater til fremføring med langvarig frigivelse af peptider |
Country Status (13)
Country | Link |
---|---|
US (2) | US8206735B2 (da) |
EP (1) | EP2054073B1 (da) |
JP (1) | JP5231412B2 (da) |
KR (2) | KR101466933B1 (da) |
CN (1) | CN101511380B (da) |
BR (1) | BRPI0715469A2 (da) |
CA (1) | CA2657911C (da) |
DK (1) | DK2054073T3 (da) |
ES (1) | ES2531679T3 (da) |
HK (1) | HK1131751A1 (da) |
MX (1) | MX2009000434A (da) |
RU (1) | RU2456018C2 (da) |
WO (1) | WO2008008363A1 (da) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7731947B2 (en) | 2003-11-17 | 2010-06-08 | Intarcia Therapeutics, Inc. | Composition and dosage form comprising an interferon particle formulation and suspending vehicle |
US11246913B2 (en) | 2005-02-03 | 2022-02-15 | Intarcia Therapeutics, Inc. | Suspension formulation comprising an insulinotropic peptide |
PL2359808T3 (pl) | 2006-08-09 | 2013-10-31 | Intarcia Therapeutics Inc | Osmotyczne systemy dostawcze i zespoły tłokowe |
CA2683610C (en) | 2007-04-23 | 2013-01-08 | Intarcia Therapeutics, Inc. | Suspension formulations of insulinotropic peptides and uses thereof |
US20090081276A1 (en) * | 2007-08-13 | 2009-03-26 | Eben Alsberg | Bioresorbable implant composition |
KR20100057048A (ko) * | 2007-09-11 | 2010-05-28 | 몬도바이오테크 래보래토리즈 아게 | 펩티드 his-ser-leu-gly-lys-trp-leu-gly-his-pro-asp-lys-phe 단독 또는 펩티드 gly-arg-gly-asp-asn-pro-oh와의 배합물의 치료제로서의 용도 |
US20090202481A1 (en) * | 2008-02-08 | 2009-08-13 | Qps Llc | Composition for Sustained Release Delivery of Proteins or Peptides |
DK2240155T3 (da) | 2008-02-13 | 2012-09-17 | Intarcia Therapeutics Inc | Indretninger, formuleringer og fremgangsmåder til levering af flere gavnlige midler |
ES2550160T3 (es) | 2008-03-27 | 2015-11-04 | Clinuvel Pharmaceuticals Limited | Terapia para el vitíligo |
AU2009200540A1 (en) * | 2008-07-03 | 2010-01-21 | Induce Biologics Inc. | Use of immobilized antagonists for enhancing growth factor containing bioimplant effectiveness |
KR101823699B1 (ko) | 2009-09-28 | 2018-01-30 | 인타르시아 세라퓨틱스 인코포레이티드 | 실질 항정상태 약물 전달의 신속 확립 및/또는 종결 |
IE20100174A1 (en) * | 2010-03-25 | 2012-02-29 | Trinity College Dublin | Transdermal administration of peptides |
US9364518B2 (en) | 2010-06-24 | 2016-06-14 | Torrent Pharmaceuticals Limited | Pharmaceutical composition containing goserelin for in-situ implant |
US20120208755A1 (en) | 2011-02-16 | 2012-08-16 | Intarcia Therapeutics, Inc. | Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers |
CN102796165B (zh) * | 2011-05-24 | 2014-02-26 | 首都医科大学 | 京都酚逆序列修饰的脂肪胺/醇衍生物及其制备方法和应用 |
KR102370470B1 (ko) | 2013-03-15 | 2022-03-04 | 헤론 테라퓨틱스 인코포레이티드 | 폴리오르토에스테르 및 비프로톤성 용매의 조성물 |
WO2015032981A1 (en) * | 2013-09-09 | 2015-03-12 | Lek Pharmaceuticals D.D. | Erythropoietin conjugates having oral bioavailability |
CN105764491A (zh) | 2013-12-09 | 2016-07-13 | 度瑞公司 | 药物活性剂复合物、聚合物复合物,以及包括其的组合物和方法 |
US9889085B1 (en) | 2014-09-30 | 2018-02-13 | Intarcia Therapeutics, Inc. | Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c |
US20160106804A1 (en) * | 2014-10-15 | 2016-04-21 | Yuhua Li | Pharmaceutical composition with improved stability |
US20170239335A1 (en) * | 2014-10-16 | 2017-08-24 | Piramal Enterprises Limited | Stable injectable composition of pharmaceutically active agents and process for its preparation |
WO2016059592A1 (en) * | 2014-10-16 | 2016-04-21 | Piramal Enterprises Limited | Stable injectable composition of peptide drugs and process for its preparation |
US10046058B2 (en) * | 2014-12-02 | 2018-08-14 | Rezolute, Inc. | Use of hydrophobic organic acids to increase hydrophobicity of proteins and protein conjugates |
MX2017015504A (es) | 2015-06-03 | 2018-05-15 | Intarcia Therapeutics Inc | Sistemas de colocacion y remoción de implante. |
MY187047A (en) * | 2015-06-12 | 2021-08-27 | Novo Nordisk As | Selective pyy compounds and uses thereof |
KR20180054627A (ko) | 2015-09-21 | 2018-05-24 | 테바 파마슈티컬스 인터내셔널 게엠베하 | 서방형 올란자핀 제제 |
AU2017268161B2 (en) | 2016-05-16 | 2020-03-12 | Intarcia Therapeutics, Inc. | Glucagon-receptor selective polypeptides and methods of use thereof |
USD860451S1 (en) | 2016-06-02 | 2019-09-17 | Intarcia Therapeutics, Inc. | Implant removal tool |
USD840030S1 (en) | 2016-06-02 | 2019-02-05 | Intarcia Therapeutics, Inc. | Implant placement guide |
CN107753953B (zh) * | 2016-08-18 | 2021-06-08 | 江苏众红生物工程创药研究院有限公司 | 聚乙二醇化激肽原酶的制剂及其应用 |
US11174288B2 (en) | 2016-12-06 | 2021-11-16 | Northeastern University | Heparin-binding cationic peptide self-assembling peptide amphiphiles useful against drug-resistant bacteria |
AU2018206539A1 (en) | 2017-01-03 | 2019-07-18 | Intarcia Therapeutics, Inc. | Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug |
US10646443B2 (en) | 2017-03-20 | 2020-05-12 | Teva Pharmaceuticals International Gmbh | Sustained release olanzapine formulations |
CN112638400A (zh) * | 2018-06-25 | 2021-04-09 | 泰坦医药品公司 | 用于释放亲脂性或两亲性药用物质的植入物 |
KR102388028B1 (ko) * | 2018-07-31 | 2022-04-20 | 주식회사 레모넥스 | 폴리펩타이드 전달용 조성물 |
CN109908407A (zh) * | 2019-03-14 | 2019-06-21 | 西南交通大学 | 具有一氧化氮储存性能的功能薄膜材料及其制备方法 |
WO2020205537A1 (en) * | 2019-03-29 | 2020-10-08 | Allegheny Singer Research Institute | Covalent modification and controlled delivery of mu opioid receptor antagonists |
CN113368041B (zh) * | 2020-07-17 | 2023-01-03 | 丽珠医药集团股份有限公司 | 药物组合物、缓释制剂及其制备方法 |
EP4277661A1 (en) | 2021-01-18 | 2023-11-22 | Anton Frenkel | Pharmaceutical dosage form |
BR102021001712A2 (pt) * | 2021-01-29 | 2022-08-16 | Edson Luiz Peracchi | Implante subcutâneo reabsorvível de longa duração com liberação prolongada de substância farmacologicamente ativa pré-concentrada em polímero para tratamento da diabetes mellitus tipo 2 e processo |
WO2023281406A1 (en) | 2021-07-06 | 2023-01-12 | Mark Hasleton | Treatment of serotonin reuptake inhibitor withdrawal syndrome |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2551756B2 (ja) | 1985-05-07 | 1996-11-06 | 武田薬品工業株式会社 | ポリオキシカルボン酸エステルおよびその製造法 |
JPH01254699A (ja) | 1988-04-05 | 1989-10-11 | Kodama Kk | インスリン誘導体及びその用途 |
US4938763B1 (en) | 1988-10-03 | 1995-07-04 | Atrix Lab Inc | Biodegradable in-situ forming implants and method of producing the same |
US5702716A (en) | 1988-10-03 | 1997-12-30 | Atrix Laboratories, Inc. | Polymeric compositions useful as controlled release implants |
US5324519A (en) | 1989-07-24 | 1994-06-28 | Atrix Laboratories, Inc. | Biodegradable polymer composition |
US5487897A (en) | 1989-07-24 | 1996-01-30 | Atrix Laboratories, Inc. | Biodegradable implant precursor |
USRE37950E1 (en) * | 1990-04-24 | 2002-12-31 | Atrix Laboratories | Biogradable in-situ forming implants and methods of producing the same |
AU2605592A (en) | 1991-10-15 | 1993-04-22 | Atrix Laboratories, Inc. | Polymeric compositions useful as controlled release implants |
EP0560014A1 (en) | 1992-03-12 | 1993-09-15 | Atrix Laboratories, Inc. | Biodegradable film dressing and method for its formation |
AU682061B2 (en) | 1993-09-17 | 1997-09-18 | Novo Nordisk A/S | Acylated insulin |
US5681873A (en) | 1993-10-14 | 1997-10-28 | Atrix Laboratories, Inc. | Biodegradable polymeric composition |
ES2171186T3 (es) | 1994-04-08 | 2002-09-01 | Atrix Lab Inc | Composiciones liquidas de difusion. |
US5552771A (en) | 1994-06-10 | 1996-09-03 | Leyden; Roger J. | Retractable sensor for an alarm system |
US5512549A (en) | 1994-10-18 | 1996-04-30 | Eli Lilly And Company | Glucagon-like insulinotropic peptide analogs, compositions, and methods of use |
US5693609A (en) | 1994-11-17 | 1997-12-02 | Eli Lilly And Company | Acylated insulin analogs |
US5869602A (en) | 1995-03-17 | 1999-02-09 | Novo Nordisk A/S | Peptide derivatives |
US5736152A (en) | 1995-10-27 | 1998-04-07 | Atrix Laboratories, Inc. | Non-polymeric sustained release delivery system |
PT944648E (pt) | 1996-08-30 | 2007-06-26 | Novo Nordisk As | Derivados do glp-1. |
WO1998008872A1 (en) | 1996-08-30 | 1998-03-05 | Novo Nordisk A/S | Glp-2 derivatives |
US20020012942A1 (en) | 1998-01-22 | 2002-01-31 | Regents Of The University Of Minnesota | Polypeptides with a4 integrin subunit related activity |
AU3247799A (en) | 1998-02-27 | 1999-09-15 | Novo Nordisk A/S | Glp-1 derivatives of glp-1 and exendin with protracted profile of action |
US6261583B1 (en) | 1998-07-28 | 2001-07-17 | Atrix Laboratories, Inc. | Moldable solid delivery system |
US6565874B1 (en) | 1998-10-28 | 2003-05-20 | Atrix Laboratories | Polymeric delivery formulations of leuprolide with improved efficacy |
US6143314A (en) | 1998-10-28 | 2000-11-07 | Atrix Laboratories, Inc. | Controlled release liquid delivery compositions with low initial drug burst |
US6355657B1 (en) | 1998-12-30 | 2002-03-12 | Atrix Laboratories, Inc. | System for percutaneous delivery of opioid analgesics |
US6461631B1 (en) | 1999-11-16 | 2002-10-08 | Atrix Laboratories, Inc. | Biodegradable polymer composition |
US7060675B2 (en) | 2001-02-15 | 2006-06-13 | Nobex Corporation | Methods of treating diabetes mellitus |
US6858580B2 (en) | 2001-06-04 | 2005-02-22 | Nobex Corporation | Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
US7164005B2 (en) | 2002-10-17 | 2007-01-16 | Alkermes, Inc. | Microencapsulation and sustained release of biologically active polypeptides |
CN101018562A (zh) * | 2003-02-07 | 2007-08-15 | 加州大学董事会 | Nell肽表达系统和nell肽的骨形成活性 |
JP4951344B2 (ja) | 2004-08-24 | 2012-06-13 | 第一三共株式会社 | 生理活性ペプチド液状製剤 |
RS53890B1 (en) * | 2004-11-10 | 2015-08-31 | Tolmar Therapeutics, Inc. | STABILIZED POLYMER DELIVERY SYSTEM |
-
2007
- 2007-07-11 MX MX2009000434A patent/MX2009000434A/es active IP Right Grant
- 2007-07-11 JP JP2009519503A patent/JP5231412B2/ja active Active
- 2007-07-11 ES ES07810318.1T patent/ES2531679T3/es active Active
- 2007-07-11 KR KR1020097002817A patent/KR101466933B1/ko active IP Right Grant
- 2007-07-11 RU RU2009103210/15A patent/RU2456018C2/ru not_active IP Right Cessation
- 2007-07-11 KR KR1020147023622A patent/KR20140109509A/ko not_active Application Discontinuation
- 2007-07-11 WO PCT/US2007/015770 patent/WO2008008363A1/en active Application Filing
- 2007-07-11 CA CA2657911A patent/CA2657911C/en not_active Expired - Fee Related
- 2007-07-11 CN CN2007800288591A patent/CN101511380B/zh not_active Expired - Fee Related
- 2007-07-11 US US11/827,260 patent/US8206735B2/en active Active
- 2007-07-11 DK DK07810318T patent/DK2054073T3/da active
- 2007-07-11 BR BRPI0715469-0A patent/BRPI0715469A2/pt not_active Application Discontinuation
- 2007-07-11 EP EP07810318.1A patent/EP2054073B1/en active Active
-
2009
- 2009-12-08 HK HK09111477.0A patent/HK1131751A1/xx not_active IP Right Cessation
-
2012
- 2012-05-25 US US13/480,544 patent/US8840915B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
MX2009000434A (es) | 2009-01-29 |
CA2657911A1 (en) | 2008-01-17 |
KR101466933B1 (ko) | 2014-12-01 |
EP2054073A1 (en) | 2009-05-06 |
US20080020016A1 (en) | 2008-01-24 |
EP2054073A4 (en) | 2010-06-23 |
US8206735B2 (en) | 2012-06-26 |
EP2054073B1 (en) | 2014-11-26 |
HK1131751A1 (en) | 2010-02-05 |
US20120237476A1 (en) | 2012-09-20 |
JP2009543776A (ja) | 2009-12-10 |
KR20140109509A (ko) | 2014-09-15 |
KR20090043510A (ko) | 2009-05-06 |
CN101511380B (zh) | 2012-12-12 |
WO2008008363A1 (en) | 2008-01-17 |
ES2531679T3 (es) | 2015-03-18 |
JP5231412B2 (ja) | 2013-07-10 |
US8840915B2 (en) | 2014-09-23 |
RU2009103210A (ru) | 2010-08-20 |
BRPI0715469A2 (pt) | 2013-03-12 |
CN101511380A (zh) | 2009-08-19 |
RU2456018C2 (ru) | 2012-07-20 |
CA2657911C (en) | 2012-02-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2054073T3 (da) | Farmaceutiske præparater til fremføring med langvarig frigivelse af peptider | |
LTC2140867I2 (lt) | Farmacinė kompozicija | |
DK2046264T3 (da) | Fremgangsmåder til fremstillingen af sammensætninger med film | |
DK2011486T3 (da) | Farmaceutiske sammensætninger af rifaximin | |
DK2345410T3 (da) | Farmaceutisk sammensætning til modificeret frigivelse | |
DK2358355T3 (da) | Farmaceutisk sammensætning af en potent HCV-inhibitor til oral indgivelse | |
SMAP200800064A (it) | Composizioni farmaceutiche di anticorpi anti-cd40 antagonisti | |
DK3300743T3 (da) | Fremgangsmåder til indgivelse af vaccine | |
BRPI0715712A2 (pt) | Composição farmacêutica | |
DK2079456T3 (da) | Farmaceutiske cyclosporinsammensætninger | |
DK3192500T3 (da) | Sammensætninger til kontinuerlig indgivelse af dopa-decarboxylasehæmmere | |
DK1984009T3 (da) | Farmaceutiske sammensætninger med forbedret stabilitet | |
BRPI0719393A2 (pt) | Composição farmacêutica | |
DK2086944T3 (da) | Fremgangsmåde til fremstilling af difluormethylpyrazolylcarboxylater | |
RU2493831C3 (ru) | Фармацевтические композиции | |
BRPI0721651A2 (pt) | Composição farmacêutica | |
DK2081551T3 (da) | Dannelse af en tørret rekonstitueret vesikel til farmaceutisk anvendelse | |
DK2152290T3 (da) | Fremgangsmåder til indgivelse af anti-il-5-antistoffer | |
DK2395840T3 (da) | Farmaceutiske formuleringer af nitazoxanid med kontrolleret frigivelse | |
DK2180882T3 (da) | Farmaceutisk faststofsammensætning af matrix-type | |
BRPI0716445A2 (pt) | composiÇço farmacÊutica | |
BRPI0720234A2 (pt) | Composição farmacêutica | |
DK2278958T3 (da) | Sammensætninger til oral frigivelse af kortikosteroider | |
DK2120884T3 (da) | Farmaceutisk sammensætning | |
ZA200810178B (en) | Pharmaceutical compositions for sustained release of phenyephrine |